Nitisinone

證據等級: L5

預測適應症: 10 個

Nitisinone: From Hereditary Tyrosinemia Type 1 to Renal Tubular Acidosis

One-Sentence Summary

Nitisinone (NTBC) is an HPPD inhibitor used as the standard treatment for hereditary tyrosinemia type 1 (HT-1). The TxGNN model predicts it may also be effective for Renal Tubular Acidosis, with 0 clinical trials and 2 publications currently supporting this direction — evidence is preliminary and limited to HT-1-associated cases.

Quick Overview

Item	Content
Original Indication	Hereditary Tyrosinemia Type 1 (HT-1) — noted in repurposing rationale; not confirmed via a structured MOA/indication field (data gap)
Predicted New Indication	Renal Tubular Acidosis
TxGNN Prediction Score	99.96%
Evidence Level	L3
Finland Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not confirmed in a structured field (DrugBank MOA lookup is flagged as a data gap). Based on known pharmacology, nitisinone is an HPPD (4-hydroxyphenylpyruvate dioxygenase) inhibitor and is the standard treatment for hereditary tyrosinemia type 1 (HT-1), a rare inherited disorder of tyrosine metabolism.

Renal tubular dysfunction — which can present as proximal renal tubular acidosis or Fanconi syndrome — is a well-recognized complication of untreated HT-1, caused by accumulation of the toxic metabolite succinylacetone. Published cohort data show that nitisinone therapy improves renal tubular function in HT-1 patients, which is mechanistically consistent with the TxGNN prediction.

Importantly, this evidence supports nitisinone's benefit for renal tubular acidosis secondary to HT-1, not renal tubular acidosis of general or unrelated etiology. Any downstream indication should be scoped specifically to "HT-1-associated" renal tubular dysfunction rather than a broad renal tubular acidosis label.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

PMID	Year	Type	Journal	Key Findings
25172236	2014	Cohort	Molecular Genetics and Metabolism	Describes early effect of NTBC on renal tubular dysfunction in HT-1 patients; renal tubular disease is a recognized HT-1 complication that has been poorly studied prior to this work
27109516	2016	Case Series	Indian Journal of Gastroenterology	Case series of 4 children with tyrosinemia treated with NTBC; 3 patients maintained normal liver function and undetectable urine succinylacetone with no renal tubular complications on long-term NTBC therapy

Finland Market Information

Nitisinone is currently not marketed in Finland (0 authorizations on record), so no marketing-authorization details are available.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Mechanistic plausibility is strong (HT-1-associated renal tubular dysfunction is a well-documented complication that improves with NTBC), but supporting evidence is limited to one cohort study and one case series — no RCTs or registered clinical trials exist for this specific indication, and the drug is not currently marketed in Finland.

To proceed, the following is needed:

TFDA/Fimea package insert data (warnings, contraindications) — currently a blocking data gap
Structured DrugBank MOA confirmation
Drug-drug interaction data (current DDI query returned no results)
Clarification that the target indication is scoped to HT-1-associated renal tubular acidosis, not general-etiology cases
Finland marketing authorization / import pathway assessment given current "not marketed" status
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.